Garrett Scott, MD
Glaucoma Specialist · Hillsboro, ORNPI 1659499507
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $2,383 of the $3,583 with a category attached, or 66.5%. 26 manufacturers reported payments, led by Rxsight Inc at 35.3% of the total. Reporting peaked in 2024 at $1,522 and has fallen 50.6% since, to $753 in 2025.
Across 110 payments — averaging $32.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Rxsight Inc$1K
- AbbVie$511
- Regeneron Healthcare Solutions, Inc.$374
- Thea Pharma Inc.$163
- Amgen$152
- Sun Pharmaceutical Industries Inc.$150
- plus $969 from 20 others
What the payments were for
- Food & beverage$2,38367%
- Education$1,20033%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Rxsight Inc | 4 | $1,263 |
| AbbVie(2 entities) | 24 | $511 |
| Regeneron Healthcare Solutions, Inc. | 13 | $374 |
| Thea Pharma Inc. | 10 | $163 |
| Amgen(2 entities) | 7 | $152 |
| Sun Pharmaceutical Industries Inc. | 8 | $150 |
| Biotissue Holdings Inc. | 3 | $122 |
| Bausch & Lomb Americas Inc. | 5 | $116 |
| Genentech USA, Inc. | 6 | $89 |
| Johnson & Johnson Surgical Vision, Inc. | 2 | $88 |
| Kala Pharmaceuticals, Inc. | 3 | $64 |
| Aerie Pharmaceuticals, Inc. | 3 | $62 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 3 | $62 |
| NEW World Medical,inc. | 2 | $55 |
| Oyster Point Pharma, Inc. | 3 | $53 |
| AstraZeneca | 2 | $43 |
| Tarsus Pharmaceuticals, Inc. | 2 | $38 |
| Novartis | 2 | $30 |
| Optos, Inc. | 1 | $28 |
| Astellas Pharma US Inc | 1 | $22 |
| Apellis Pharmaceuticals, Inc. | 1 | $21 |
| Omeros Corporation | 1 | $19 |
| Mallinckrodt Hospital Products Inc. | 1 | $18 |
| Glaukos Corporation | 1 | $15 |
| Iridex Corporation | 1 | $12 |
| Alcon | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
Too few glaucoma specialist providers in Oregonto place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 188 | $124,586 |
| LumiganBimatoprost | 42 | $24,157 |
| XiidraLifitegrast | 18 | $13,471 |
| Cyclosporine | 52 | $12,006 |
| Fluorometholone | 179 | $11,557 |
| Prednisolone Acetate | 198 | $7,946 |
| Latanoprost | 751 | $7,848 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 55 | $6,662 |
| Brinzolamide | 35 | $6,179 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 20 | $5,661 |
| CombiganBrimonidine Tartrate/Timolol | 21 | $4,989 |
| VyzultaLatanoprostene Bunod | 14 | $4,058 |
| Tobramycin-DexamethasoneTobramycin/Dexamethasone | 80 | $3,789 |
| Loteprednol Etabonate | 19 | $3,198 |
| Timolol Maleate | 275 | $2,862 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Lumigan, Combigan | $511 | $153,732251 claims |
| Bausch & Lomb Americas Inc.Xiidra, Vyzulta | $116 | $17,52832 claims |
| AlconSimbrinza | $12 | $5,66120 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate | $62 | $3,19819 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few glaucoma specialist providers in Oregonon file to place this against a meaningful peer group, so we don't.
Other glaucoma specialist in Hillsboro
- Justin SpauldingMedford$69K
- Steven MansbergerPortland$28K
- Hana TakusagawaEugene$3K
- Helen KoenigsmanMedford$2K
- Brendan ButlerMedford$1K
- Jonathan YoungTigard$1K
- Zoey StoumbosPortland$1K
- Michael GalePortland$1K
- Christine PetersenMedford$1K
- Charles WeberOregon City$453
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.